Find therapies in clinical trials near you – page 734

Long-Term Safety Study of BI 3720931 for Patients with Cystic Fibrosis from a Previous Trial

Long-Term Safety Study of BI 3720931 for Patients with Cystic Fibrosis from a Previous Trial

Long-Term Study of Tofacitinib for Children and Teens with Juvenile Idiopathic Arthritis

Long-Term Study of Tofacitinib for Children and Teens with Juvenile Idiopathic Arthritis

Study of Letetresgene Autoleucel for Patients with Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Study of Letetresgene Autoleucel for Patients with Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Study on the Safety and Effectiveness of BI 3720931 for Adults with Cystic Fibrosis Who Cannot Use CFTR Modulators

Study on the Safety and Effectiveness of BI 3720931 for Adults with Cystic Fibrosis Who Cannot Use CFTR Modulators

Study on Long-Term Safety of Secukinumab for Patients with Polymyalgia Rheumatica

Study of Pertuzumab and Trastuzumab for Patients with Solid Malignant Tumors from Previous Pertuzumab Trials

Study of Pertuzumab and Trastuzumab for Patients with Solid Malignant Tumors from Previous Pertuzumab Trials

Study on the Safety and Effects of Afamelanotide for Patients with Early Parkinson's Disease

Study on the Safety and Effects of Afamelanotide for Patients with Early Parkinson's Disease

Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments

Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments

Study of Eltrekibart for Adults with Moderate to Severe Hidradenitis Suppurativa

Study of Eltrekibart for Adults with Moderate to Severe Hidradenitis Suppurativa

Study of ASP1570 Alone or with Pembrolizumab for Adults with Advanced Solid Tumors

Study of ASP1570 Alone or with Pembrolizumab for Adults with Advanced Solid Tumors

Study of SKB264 for Patients with Advanced Solid Tumors Not Responding to Standard Treatments

Study of SKB264 for Patients with Advanced Solid Tumors Not Responding to Standard Treatments

Study on Reduced Dose of Alteplase for Patients with Intermediate-High-Risk Acute Pulmonary Embolism

Study on Reduced Dose of Alteplase for Patients with Intermediate-High-Risk Acute Pulmonary Embolism